title: Development of a magnetisable solid-phase fluoroimmunoassay for primaquine and carboxyprimaquine.
abstract: Primaquine coupled to keyhole limpet hemocyanin was used as an immunogen to produce antiprimaquine antibodies in three sheep. The antisera obtained were characterised by the increase in fluorescence polarisation found upon binding to fluorescein-labelled primaquine prepared via same route. All sheep showed a good antibody response and one antiserum was coupled to magnetisable solid-phase particles to facilitate the separation of the antibody bound from free labelled antigen and the removal of interfering components which may be present in the sample. The fluoroimmunoassay requires addition of 100 microliters of standard or sample (urine or serum) to 100 microliters tracer (150 nmol/l) followed by 100 microliters of magnetisable solid-phase particles (12.5 g/l). After one hour incubation followed by the usual washing and eluting procedures, using a magnetic rack, the fluorescence of the supernatant was measured directly in a fluorimeter. Sodium salicylate was incorporated in the tracer solution to block the non-specific binding of tracer to the protein in serum samples. Cross-reactivity studies showed that the antibodies have high specificity for the 8-aminoquinoline nucleus but not to the 8-N-aminobutyl side chain. Thus carboxyprimaquine cross-reacted equally with primaquine and the assay can be used to measure their combined level. After extraction of primaquine from a basified sample with methylene chloride, the assay may be applied for the quantitation of either primaquine (in the organic phase) or its acidic metabolites including carboxyprimaquine (in the aqueous phase) separately. This approach was applied for the determination of total primaquine (primaquine and its metabolites) and extracted primaquine in urine samples following a single oral dose of 45 mg primaquine.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Chemical Pathology, St. Bartholomew's Hospital, London, UK.
authors.forename: I H
authors.initials: IH
authors.lastname: al-Abdulla
authors.forename: A M
authors.initials: AM
authors.lastname: Sidki
authors.forename: J
authors.initials: J
authors.lastname: Landon
authors.forename: F J
authors.initials: FJ
authors.lastname: Rowell
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D015200:Fluoroimmunoassay / Q000379:methods*; D006801:Humans; D008288:Malaria / Q000097:blood* / Q000188:drug therapy; D008297:Male; D011319:Primaquine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D012756:Sheep; D013997:Time Factors
chemical_list: D011319:Primaquine